Health Canada has discovered that the private clinic Grifols green-lit plasma donors who posed a disease risk. This finding raises concerns about donor screening practices.

Grifols, S.A. (GRFS) has reported robust growth in its biopharma sector, primarily attributed to the strong performance of its products Gamunex and Yimmugo.

Grifols, the Catalan biopharmaceutical group, announced a 22% increase in profits to 73 million euros at the start of the year, driven by its biopharmaceutical division, with overall revenues growing 3% to 1.7 billion euros.

Health Canada has placed new terms and conditions on plasma donation company Grifols' centers following multiple failed inspections that revealed 'recurring, systemic deficiencies,' while also reviewing two deaths in Winnipeg linked to the company, leading to new restrictions in Canada.

Grifols, a global healthcare company, has officially approved the initial public offering (IPO) of its US biopharma business, signaling a strategic move for the company's future.

Grifols is collaborating with patient associations to advance research into plasma-based therapies, which are crucial for patients with rare diseases, aiming to accelerate early diagnosis.

A unit of FOXO is set to acquire four blood collection centers in the U.S. from a Grifols subsidiary.

Grifols is utilizing artificial intelligence in various projects, ranging from exploratory analysis to identifying biomarkers for the early anticipation of diseases like Parkinson's.

Grifols is confident that a US stock market listing will help correct its market value, following a general shareholders' meeting that approved a 10% capital reduction.

Grifols apuesta por este modelo formativo con el que ha conseguido identificar talento y ajustar el perfil académico al puesto de trabajo con profesionales más especializados

Health Canada has announced new conditions for Grifols, S.A. (GRFS) plasma collection centers, impacting the company's operations in the country.

Spanish pharmaceutical company Grifols is listing its Biopharma division on Wall Street in a strategic move to boost its stock and reduce corporate debt.

Spanish pharmaceutical company Grifols has advanced its refinancing efforts by agreeing to a new 2 billion euro revolving credit line, which doubles its current facility and extends its maturity by 6.5 years.

The Spanish multinational pharmaceutical company Grifols more than doubled its profit, with revenue increasing by 4.3% to 7.524 billion euros, driven by strong performance in its bioscience division.

Spanish pharmaceutical company Grifols announced a net profit of 227 million euros for the first half of the year, marking a 28.7% increase despite a 2.8% drop in revenue to 3.574 billion euros.

Grifols, a hemoderivatives company, is separating a subsidiary from its main structure to strengthen its autonomy before taking it public on Wall Street.

Spanish Prime Minister Pedro Sánchez laid the first stone for Grifols' new plant in Lliçà de Vall, an investment of 160 million euros expected to begin operations in 2030.

A New York judge investigating a defamation lawsuit has rejected the request from the short-seller fund Gotham for protection under journalistic privileges. This ruling is part of the ongoing legal battle involving Grifols.

Findings from the largest proteomic study on Parkinson's disease, conducted by Grifols, indicate that biological changes associated with the condition can be observed up to 12 years before a clinical diagnosis.

Grifols, a Spanish health care company, operates clinics in Canada that collect blood plasma from donors in exchange for an honorarium.